PE20090223A1 - Compuestos triciclicos como inhibidores de metaloproteinasas matriciales - Google Patents

Compuestos triciclicos como inhibidores de metaloproteinasas matriciales

Info

Publication number
PE20090223A1
PE20090223A1 PE2008000773A PE2008000773A PE20090223A1 PE 20090223 A1 PE20090223 A1 PE 20090223A1 PE 2008000773 A PE2008000773 A PE 2008000773A PE 2008000773 A PE2008000773 A PE 2008000773A PE 20090223 A1 PE20090223 A1 PE 20090223A1
Authority
PE
Peru
Prior art keywords
sulfonamide
dibenzo
metaloproteinases
matricial
compounds
Prior art date
Application number
PE2008000773A
Other languages
English (en)
Inventor
Wei Li
Jianchang Li
Yuchuan Wu
Junjun Wu
Rajeev Hotchandain
Steve Tam
Tarek Mansour
Joseph P Sypek
Iain Mcfadyen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20090223A1 publication Critical patent/PE20090223A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO TRICICLICO DE FORMULA (I), DONDE X ES O, S, S(O) O S(O)2; Y ES S(O) O S(O)2; R1 ES UNA VALINA LIGADA A N CON UN TERMINAL C CARBOXILO PROTEGIDO O LIBRE; R2 ES -C(O)OR6, -C(S)OR6, -C(S)R7, ENTRE OTROS; R3 Y R4 SON H, -CN, -NO2, ENTRE OTROS; R6 ES H, -C(O)R7, -C(O)NR7R8, ENTRE OTROS; R7 Y R8 SON H, -OH, -NH2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO (R)-2-(8-(4,4-DIMETIL-2-OXO-2,4-DIHIDRO-1H-BENZO[d][1,3]OXAZIN-6-IL)DIBENZO[b,d]FURANO-3-SULFONAMIDO)-3-METILBUTANOICO, ACIDO (S)-2-(8-(3-(DIMETILAMINO)PROP-1-INIL)DIBENZO[b,d]FURANO-3-SULFONAMIDO)-3-BUTANOICO, ACIDO (S)-3-METIL-2-(8-(PIRIDIN-3-IL)DIBENZO[b,d]FURANO-3-SULFONAMIDO)BUTANOICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD INHIBITORIA DE LAS METALOPROTEINASAS MATRICIALES (MMP), PARTICULARMENTE, MMP-12 Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, TRANSTORNOS METABOLICOS, CRECIMIENTO DE TUMORES, ENTRE OTRAS
PE2008000773A 2007-05-04 2008-04-30 Compuestos triciclicos como inhibidores de metaloproteinasas matriciales PE20090223A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92756307P 2007-05-04 2007-05-04

Publications (1)

Publication Number Publication Date
PE20090223A1 true PE20090223A1 (es) 2009-03-08

Family

ID=39944224

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000773A PE20090223A1 (es) 2007-05-04 2008-04-30 Compuestos triciclicos como inhibidores de metaloproteinasas matriciales

Country Status (11)

Country Link
US (1) US20100227859A1 (es)
EP (1) EP2144893A2 (es)
JP (1) JP2010526106A (es)
AR (1) AR066412A1 (es)
CA (1) CA2685389A1 (es)
CL (1) CL2008001257A1 (es)
MX (1) MX2009011749A (es)
PA (1) PA8779101A1 (es)
PE (1) PE20090223A1 (es)
TW (1) TW200900397A (es)
WO (1) WO2008137816A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1987034B1 (en) * 2006-02-22 2011-07-20 Vertex Pharmceuticals Incorporated Spiro condensed piperidines as modulators of muscarinic receptors
US9273021B2 (en) 2009-02-05 2016-03-01 Trustees Of Boston College Dibenzofuran derivatives as inhibitors of fructose 1,6-bisphosphatase and methods of use thereof
US8735414B2 (en) * 2009-04-06 2014-05-27 Ptc Therapeutics, Inc. Indole derivatives and methods for antiviral treatment
CN104995559B (zh) 2013-02-08 2020-04-07 三菱瓦斯化学株式会社 抗蚀剂组合物、抗蚀图案形成方法和用于其的多元酚衍生物
AU2014249192B2 (en) 2013-03-11 2017-12-21 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
JP7026439B2 (ja) 2014-12-25 2022-02-28 三菱瓦斯化学株式会社 化合物、樹脂、リソグラフィー用下層膜形成材料、リソグラフィー用下層膜、パターン形成方法及び精製方法
JP6766803B2 (ja) 2015-03-31 2020-10-14 三菱瓦斯化学株式会社 レジスト組成物、レジストパターン形成方法、及びそれに用いるポリフェノール化合物
CN107533291B (zh) * 2015-03-31 2021-06-11 三菱瓦斯化学株式会社 化合物、抗蚀剂组合物及使用其的抗蚀图案形成方法
US11143962B2 (en) 2015-08-31 2021-10-12 Mitsubishi Gas Chemical Company, Inc. Material for forming underlayer film for lithography, composition for forming underlayer film for lithography, underlayer film for lithography and production method thereof, pattern forming method, resin, and purification method
KR20180048799A (ko) 2015-08-31 2018-05-10 미쯔비시 가스 케미칼 컴파니, 인코포레이티드 리소그래피용 하층막 형성재료, 리소그래피용 하층막 형성용 조성물, 리소그래피용 하층막 및 그 제조방법, 그리고 레지스트 패턴형성방법
WO2017043561A1 (ja) 2015-09-10 2017-03-16 三菱瓦斯化学株式会社 化合物、樹脂、レジスト組成物又は感放射線性組成物、レジストパターン形成方法、アモルファス膜の製造方法、リソグラフィー用下層膜形成材料、リソグラフィー用下層膜形成用組成物、回路パターンの形成方法、及び、精製方法
US10042251B2 (en) 2016-09-30 2018-08-07 Rohm And Haas Electronic Materials Llc Zwitterionic photo-destroyable quenchers
GB201617339D0 (en) 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
KR102435507B1 (ko) * 2019-07-31 2022-08-24 일동제약(주) 신규 벤조퓨란 유도체 및 이의 용도
CN113929645B (zh) * 2021-12-15 2022-03-11 长沙普济生物科技股份有限公司 一种光催化合成苯并呋喃基氨基酸表面活性剂的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU735013B2 (en) * 1996-09-04 2001-06-28 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses
AU736347B2 (en) * 1996-09-04 2001-07-26 Warner-Lambert Company Compounds for and a method of inhibiting matrix metalloproteinases
PT1210326E (pt) * 1999-08-18 2004-07-30 Warner Lambert Co Compostos de acido hidroxamico uteis como inibidores de metaloproteinases da matriz
MXPA01013172A (es) * 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
US20030157110A1 (en) * 2002-01-07 2003-08-21 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
EP2074107A2 (en) * 2006-10-27 2009-07-01 Wyeth a Corporation of the State of Delaware Tricyclic compounds as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
US20100227859A1 (en) 2010-09-09
JP2010526106A (ja) 2010-07-29
AR066412A1 (es) 2009-08-19
EP2144893A2 (en) 2010-01-20
CL2008001257A1 (es) 2008-07-04
WO2008137816A2 (en) 2008-11-13
TW200900397A (en) 2009-01-01
PA8779101A1 (es) 2008-12-18
WO2008137816A8 (en) 2010-01-28
CA2685389A1 (en) 2008-11-13
MX2009011749A (es) 2009-11-11
WO2008137816A3 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
PE20090223A1 (es) Compuestos triciclicos como inhibidores de metaloproteinasas matriciales
CL2012000059A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidina; proceso de preparacion; composicion farmaceutica que los comprende; y su uso como inhbidores de trk-quinasa para el tratamiento de enfermedades o trastornos tales como dolor, cancer, inflamacion; entre otras.
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
BRPI0511433A (pt) derivados de quinolina substituìda como inibidores de cinesina mitótica
EA201001455A1 (ru) Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3)
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
ECSP088765A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
UA109667C2 (xx) Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
AR077220A1 (es) {5-[4-(1,1-dioxo-1-tiomorfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il} amida del acido ciclopropanocarboxilico inhibidor de quinasas janus(jak), composiciones farmaceuticas que lo contienen y uso de los mismos para tratar afecciones inflamatorias, autoinmunes y proliferativas.
BRPI0707493B8 (pt) composto inibidor de enzimas e1 ativadoras e composição farmacêutica contendo o referido composto
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
EA201201663A1 (ru) Производные 2-(ариламино)-3н-имидазо[4,5-b]пиридин-6-карбоксамида и их применение в качестве ингибиторов mpges-1
MY155565A (en) Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201070988A1 (ru) Противовирусные терапевтические средства
UY33245A (es) Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
EA201591804A1 (ru) Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы
AR077221A1 (es) {5-[4-(3,3-dimetil-azetidina-1-carbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il} amida del acido ciclopropanocarboxilico inhibidor de quinasas janus(jak), en particular jak1, composiciones farmaceuticas que lo contienen y uso de los mismos para tratar afecciones inflamatorias, autoinmunes y proli
EA201070966A1 (ru) Фолаты, композиции и применение указанных композиций
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
CL2010001566A1 (es) Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune.

Legal Events

Date Code Title Description
FX Voluntary withdrawal